Biological Information
Background Information:
Cytochrome P450 (CYP) inhibition is one of the most common types of drug-drug interactions (DDI). When a drug inhibits a specific CYP isoform, it will reduce the metabolic activity toward a concomitant drug that is metabolized by this inhibited CYP isoform, resulting in the increase in the bioavailability of the victim drug, often to a point that toxicity is induced. Regulatory agencies have issued guidances recommending that all new molecular entity (NME) be screened for CYP inhibition liability, especially for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Eurofins can determine inhibition of the major CYP enzymes using drug substrates in human liver microsomes or with fluorescent substrates and recombinant human CYP enzymes.
Family:
CYP450
Sub Family:
CYP2
Protein Name:
CYP2A6
Uniprot Number:
P11509
Gene Name:
CYP2A6
Gene ID:
1548
Gene Aliases:
CPA6|CYP2A
Organism:
Human
Construct Details:
Microsomes
Tissue:
Liver
Assay Information
Assay Type:
Biochemical
Assay Sub Type:
Enzymatic
Functional Mode:
Antagonist
Detection Method:
HPLC-MS/MS
Measured Response:
Peak Area Response
Testing Information
Substrate:
2 µM Coumarin
Incubation:
5 min pre-incubation and 10 min with NADPH at 37°C
Turnaround Time
Standard:
10 Business Days
Clinical Relevance
Adverse / Beneficial Action:
CYP450 assays are designed to predict potential drug-drug interactions for screening new chemical entities.
Additional Information
Brand:
Cerep
Testing Location:
USA - St Charles, MO
RELATED SOLUTIONS